Neogen Says Australian, New Zealand Review Of Genomics Sale To Zoetis Expected To Conclude Early 2027; Zoetis Offered To Divest Some Australian Assets
https://www.sec.gov/ix?doc=/Archives/edgar/data/0000711377/000119312526447166/neog-20261104.htm
Share
Why It Matters
Neogen is selling its genomics business to Zoetis. Regulators in Australia and New Zealand are reviewing the deal, which should finish early 2027.
This read is generated by AI from raw market data and is for education only. It is not financial advice, not a signal, and not a recommendation to buy or sell.
Tickers in Play
Last session drawn · prints held ~15 minutes · licensed exchange data
Source: Benzinga · Read the original report at the publisher. Headline and figures shown for context; data may be delayed.
Disclosure: Educational and informational purposes only. Not financial advice. We educate, not advise. Market data may be delayed up to 15 minutes unless marked real-time. Past performance is not indicative of future results.